Enalare Therapeutics Expands Its Scientific Team With Appointment of Thomas Miller, PhD, as Vice President of Clinical Development

Enalare Therapeutics Inc., a biopharmaceutical company dedicated to developing novel therapies for patients suffering from life-threatening critical care conditions, announced today that it has expanded its scientific team with the appointment of Thomas Miller, Ph.D., as Vice President of Clinical Development.
Dr. Miller brings more than 20 years of experience in the development of biophysical and pharmacological interventions targeted primarily at critical care pulmonary function and attenuation of ventilator-induced lung injury. Miller is well published with an academic background in the preclinical and clinical development of novel device and drug therapies. He transitioned to industry as the pioneer of high-velocity nasal insufflation, which is now an international front-line standard of care for respiratory insufficiency. For the last 14 years, Tom has been leading clinical development for medical technologies, most recently as Executive Vice President of Clinical & Regulatory Affairs for Vixiar Medical, focused on a novel platform to assess pulmonary hemodynamics secondary to conditions such as heart failure.
“I am tremendously excited to join the Enalare team and help drive the development of our novel lead drug candidate ENA-001 for acute respiratory depression. This is an opportunity to make a major difference in care for multiple patient populations having a clear unmet need,” stated Miller. “Enalare is developing a one-of-a-kind therapy and it’s work that comes with a great sense of purpose.”
“We are thrilled to have someone of Tom’s clinical and professional expertise join our growing organization,” stated Herm Cukier, Enalare’s President and CEO. “His experience with pulmonary technologies will be a valued complement to our already outstanding scientific team as we pursue development of several products with our agnostic respiratory stimulant technology.”
“We are excited to have Dr. Miller join the Enalare Team. His background complements the direction of our strategic focus,” stated Dr. Joseph Pergolizzi, Enalare’s Head of Research & Development. “I am confident that he will make important contributions to our development activities.”
Prior to his role at Vixiar, Tom established and led clinical and scientific affairs globally for Vapotherm, playing a significant scientific role during the company’s path to an IPO. He previously directed a translational research program at Nemours (A.I. duPont Hospital for Children) and holds a faculty position with the Sidney Kimmel Medical College at Thomas Jefferson University. Dr. Miller received his Ph.D. in Medical Physiology from the Lewis Katz School of Medicine at Temple University, an MS in Kinesiology from Temple University and a BS from the University of Delaware.
About Enalare Therapeutics Inc.
Enalare Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for patients suffering from life-threatening critical care conditions, including drug overdose, post-surgery respiratory depression, and apnea of prematurity. The Company announced a partnership with BARDA earlier this year for the development of its lead compound ENA-001 as a Medical Countermeasure for mass casualty events.
###
Contact:
Morgan Wagner
Enalare Investor Relations
Mwagner@enalare.com
Source: Enalare Therapeutics Inc.